Related references
Note: Only part of the references are listed.Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
R. Bradley et al.
LANCET ONCOLOGY (2022)
Clinical management and biology of tumor dormancy in breast cancer
Stefan Werner et al.
SEMINARS IN CANCER BIOLOGY (2022)
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F. Petrelli et al.
ANNALS OF ONCOLOGY (2021)
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge
Grace G. Bushnell et al.
NPJ BREAST CANCER (2021)
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015
Lu Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds
Maxim E. Menyailo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Jack Cuzick et al.
LANCET (2020)
Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the ATRESS phenomenon
Patriek Jurrius et al.
BREAST (2020)
Breast cancer: are long-term and intermittent endocrine therapies equally effective?
Jutta Engel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Molecular Predictive and Prognostic Markers in Locoregional Management
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking
George D. Cresswell et al.
NATURE COMMUNICATIONS (2020)
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
Vincent P. Walter et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2020)
Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer
Apoorva Anandan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Lymph node infiltration, parallel metastasis and treatment success in breast cancer
Jutta Engel et al.
BREAST (2019)
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Laura Keller et al.
NATURE REVIEWS CANCER (2019)
Is invasion a necessary step for metastases in breast cancer?
Steven A. Narod et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Clonality analysis of multifocal ipsilateral breast carcinomas using X-chromosome inactivation patterns
Hayeon Kim et al.
HUMAN PATHOLOGY (2018)
Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes
Ikram Ullah et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice
Ethel R. Pereira et al.
SCIENCE (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Genetic insights into the morass of metastatic heterogeneity
Kent W. Hunter et al.
NATURE REVIEWS CANCER (2018)
Survival of de novo stage IV breast cancer patients over three decades
Dieter Hoelzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry
Dieter Hoelzel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Current approach of the axilla in patients with early-stage breast cancer
Eleftherios P Mamounas et al.
LANCET (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Correlation Factors Analysis of Breast Cancer Tumor Volume Doubling Time Measured by 3D-Ultrasound
Shuying Zhang et al.
MEDICAL SCIENCE MONITOR (2017)
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
Laura J. van t Veer et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Genomic Evolution of Breast Cancer Metastasis and Relapse
Lucy R. Yates et al.
CANCER CELL (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer
Anita Mamtani et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015
A. Vivot et al.
ANNALS OF ONCOLOGY (2017)
Pre-metastatic niches: organ-specific homes for metastases
Hector Peinado et al.
NATURE REVIEWS CANCER (2017)
The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening
Nehmat Houssami et al.
NPJ BREAST CANCER (2017)
Emerging Biological Principles of Metastasis
Arthur W. Lambert et al.
CELL (2017)
Catalog of genetic progression of human cancers: breast cancer
Christine Desmedt et al.
CANCER AND METASTASIS REVIEWS (2016)
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Metastasis as an evolutionary process
Samra Turajlic et al.
SCIENCE (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
Jack Cuzick et al.
LANCET ONCOLOGY (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
The mathematics of cancer: integrating quantitative models
Philipp M. Altrock et al.
NATURE REVIEWS CANCER (2015)
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Thordur Oskarsson et al.
CELL STEM CELL (2014)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Duveken B. Y. Fontein et al.
EUROPEAN JOURNAL OF CANCER (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma
Xiang H. -F. Zhang et al.
CELL (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch et al.
LANCET (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
Targeting dormant cancer
Julio A. Aguirre-Ghiso et al.
NATURE MEDICINE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Positive lymph nodes do not metastasize
Jutta Engel et al.
CANCER AND METASTASIS REVIEWS (2012)
Comparative Effectiveness Research in Oncology Methodology: Observational Data
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse-A European Pooled Analysis
Wolfgang Janni et al.
CLINICAL CANCER RESEARCH (2011)
TRUE RECURRENCE VERSUS NEW PRIMARY: AN ANALYSIS OF IPSILATERAL BREAST TUMOR RECURRENCES AFTER BREAST-CONSERVING THERAPY
Valerie Panet-Raymond et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
LANCET (2011)
Long-Term Patterns of In-Breast Failure in Patients With Early Stage Breast Cancer Treated With Breast-Conserving Therapy A Molecular Based Clonality Evaluation
Samuel McGrath et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Observational Methods in Comparative Effectiveness Research
John Concato et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
Andrea Veronesi et al.
BMC CANCER (2010)
Distant metastases do not metastasize
Dieter Hoelzel et al.
CANCER AND METASTASIS REVIEWS (2010)
TRUE LOCAL RECURRENCE RATE IN THE CONSERVED BREAST AFTER MAGNETIC RESONANCE IMAGING TARGETED RADIOTHERAPY
Elisabeth Whipp et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Tumor Self-Seeding by Circulating Cancer Cells
Mi-Young Kim et al.
CELL (2009)
Genes that mediate breast cancer metastasis to the brain
Paula D. Bos et al.
NATURE (2009)
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer
Maaike de Boer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Systemic spread is an early step in breast cancer
Yves Huesemann et al.
CANCER CELL (2008)
Breast cancer tumor growth estimated through mammography screening data
Harald Weedon-Fekjaer et al.
BREAST CANCER RESEARCH (2008)
The accuracy of combined versus largest diameter in staging multifocal breast cancer
Brendan J. O'Daly et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
Are we wasting our time with the sentinel technique?: Fifteen reasons to stop axilla dissection
J. Engel et al.
BREAST (2006)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement
M Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Circulating tumor cells in patients with breast cancer dormancy
SD Meng et al.
CLINICAL CANCER RESEARCH (2004)
The prognostic influence of multifocality in breast cancer patients
L Pedersen et al.
BREAST (2004)
Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial
RT Chlebowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy
IS Fentiman et al.
EUROPEAN JOURNAL OF CANCER (2003)
A molecular signature of metastasis in primary solid tumors
S Ramaswamy et al.
NATURE GENETICS (2003)
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
B Fisher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management
TE Smith et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Delayed adjuvant tamoxifen:: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
T Delozier et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
